By Davit Kirakosyan Barclays initiated coverage on Target (NYSE:TGT) with an Equalweight rating and a price target of $163.00. BTIG initiated coverage on Foot Locker (NYSE:FL)...
Orchestra BioMed Holdings, Inc. is a biomedical company. It is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
|Average||20.33 (+29.26% Upside)|
|No. of Analysts||3|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Buy||Strong Buy|
|Technical Indicators||Strong Sell||Strong Sell||Sell||Strong Sell||Strong Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Neutral||Strong Buy|